When outlining his complicated $30bn M&A transaction with Johnson & Johnson on Jan. 26, Jean-Paul Clozel reminisced on how close Actelion Pharmaceuticals Ltd. shareholders had come to exiting too early in 2011 when activist shareholder Elliott Advisors had tried to take control of the Swiss biotech at a much lower stock price.
Can Actelion Founder Clozel Recreate Another Top Biotech Post-J&J Sale?
Actelion's M&A deal with J&J vindicates the strategy of cardiologist Jean-Paul Clozel, who co-founded the Swiss firm with his wife Martine and friends in 1997, and positions him for another shot at biotech success.
More from Deals
More from Business
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.